The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to grow at a CAGR of 10.6% from 2025 to 2030. Rising incidences of acute myeloid leukemia and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost market growth further.
Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.
Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy. Such innovative approaches indicate a growing commitment to developing multifaceted treatment strategies that promise to improve patient outcomes.
Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system’s response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.
The growing incidence of AML, driven by factors such as genetic mutations, unhealthy lifestyles, and environmental hazards, underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. In December 2023, scientists at the University of Montreal secured a USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader for high-risk acute myeloid leukemia patients, aiming to enhance treatment outcomes and stimulate economic growth in Canada. The development of innovative therapies for high-risk patients, along with substantial global investments in research and development, is expected to drive market growth. Furthermore, partnerships between pharmaceutical companies and research institutions are enhancing the pace of new AML treatment development.
This product will be delivered within 1-3 business days.
Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.
Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy. Such innovative approaches indicate a growing commitment to developing multifaceted treatment strategies that promise to improve patient outcomes.
Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system’s response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.
The growing incidence of AML, driven by factors such as genetic mutations, unhealthy lifestyles, and environmental hazards, underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. In December 2023, scientists at the University of Montreal secured a USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader for high-risk acute myeloid leukemia patients, aiming to enhance treatment outcomes and stimulate economic growth in Canada. The development of innovative therapies for high-risk patients, along with substantial global investments in research and development, is expected to drive market growth. Furthermore, partnerships between pharmaceutical companies and research institutions are enhancing the pace of new AML treatment development.
Global Acute Myeloid Leukemia Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end use, and region:Disease Outlook (Revenue, USD Million, 2018 - 2030)
- Myeloblastic Leukemia
- Myelomonocytic Leukemia
- Promyelocytic Leukemia
- Monocytic Leukemia
- Other Diseases
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Chemotherapy
- Anti-metabolites
- Alkylating Agents
- Anthracycline Drugs
- Others
- Targeted Therapy
- FLT3 Inhibitors
- Rydapt
- Vanflyta
- Xospata
- IDH Inhibitors
- Tibsovo
- Rezlidhia
- Idhifa
- Mylotarg
- BCL-2 Inhibitor
- Hedgehog Pathway Inhibitor
- Immunotherapy
- Bispecific Antibodies
- Antibody-drug Conjugates
- Immune Checkpoint Inhibitors
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Other Treatments
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals and Clinics
- Specialty Centers
- Homecare Setting
- Ambulatory Care Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.4. Pipeline Analysis
Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Business Analysis
4.1. Disease Market Share, 2024 & 2030
4.2. Disease Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Myeloblastic Leukemia
4.4.1. Myeloblastic Leukemia Market, 2018 - 2030 (USD Million)
4.5. Myelomonocytic Leukemia
4.5.1. Myelomonocytic Leukemia Market, 2018 - 2030 (USD Million)
4.6. Promyelocytic Leukemia
4.6.1. Promyelocytic Leukemia Market, 2018 - 2030 (USD Million)
4.7. Monocytic Leukemia
4.7.1. Monocytic Leukemia Market, 2018 - 2030 (USD Million)
4.8. Other Diseases
4.8.1. Other Diseases Market, 2018 - 2030 (USD Million)
Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Business Analysis
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Chemotherapy
5.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
5.4.2. Anti-metabolites
5.4.3. Anti-metabolites Market, 2018 - 2030 (USD Million)
5.4.4. Alkylating Agents
5.4.5. Alkylating Agents Market, 2018 - 2030 (USD Million)
5.4.6. Anthracycline Drugs
5.4.7. Anthracycline Drugs Market, 2018 - 2030 (USD Million)
5.4.8. Others
5.4.9. Others Market, 2018 - 2030 (USD Million)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
5.5.2. FLT3 Inhibitors
5.5.3. FLT3 Inhibitors Market, 2018 - 2030 (USD Million)
5.5.3.1. Rydapt
5.5.3.1.1. Rydapt Market, 2018 - 2030 (USD Million)
5.5.3.2. Vanflyta
5.5.3.2.1. Vanflyta Market, 2018 - 2030 (USD Million)
5.5.3.3. Xospata
5.5.3.3.1. Xospata Market, 2018 - 2030 (USD Million)
5.5.4. IDH Inhibitors
5.5.5. IDH Inhibitors Market, 2018 - 2030 (USD Million)
5.5.5.1. Tibsovo
5.5.5.1.1. Tibsovo Market, 2018 - 2030 (USD Million)
5.5.5.2. Rezlidhia
5.5.5.2.1. Rezlidhia Market, 2018 - 2030 (USD Million)
5.5.5.3. Idhifa
5.5.5.3.1. Idhifa Market, 2018 - 2030 (USD Million)
5.5.6. Mylotarg
5.5.6.1. Mylotarg Market, 2018 - 2030 (USD Million)
5.5.7. BCL-2 Inhibitor
5.5.7.1. BCL-2 Inhibitor Market, 2018 - 2030 (USD Million)
5.5.8. Hedgehog Pathway Inhibitor
5.5.8.1. Hedgehog Pathway Inhibitor Market, 2018 - 2030 (USD Million)
5.6. Immunotherapy
5.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
5.6.2. Bispecific Antibodies
5.6.2.1. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
5.6.3. Antibody-drug Conjugates
5.6.3.1. Antibody-drug Conjugates Market, 2018 - 2030 (USD Million)
5.6.4. Immune Checkpoint Inhibitors
5.6.4.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
5.6.5. Chimeric Antigen Receptor (CAR) T-cell Therapy
5.6.5.1. Chimeric Antigen Receptor (CAR) T-cell Therapy Market, 2018 - 2030 (USD Million)
5.7. Other Treatments
5.7.1. Other Treatments Market, 2018 - 2030 (USD Million)
Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
6.5. Oral
6.5.1. Oral Market, 2018 - 2030 (USD Million)
Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Business Analysis
7.1. End Use Market Share, 2024 & 2030
7.2. End Use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Hospitals and Clinics
7.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
7.5. Specialty Centers
7.5.1. Specialty Centers Market, 2018 - 2030 (USD Million)
7.6. Homecare Setting
7.6.1. Homecare Setting Market, 2018 - 2030 (USD Million)
7.7. Ambulatory Care Centers
7.7.1. Ambulatory Care Centers Market, 2018 - 2030 (USD Million)
Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Astellas Pharma Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Bristol-Myers Squibb Company
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. DAIICHI SANKYO COMPANY, LIMITED
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Jazz Pharmaceuticals plc
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Novartis AG
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Otsuka Pharmaceuticals Co.,Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Pfizer Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Rigel Pharmaceuticals, Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Merck KGaA
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Sanofi
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 4. Global acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 5. Global acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 6. Global acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 7. Global acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 8. North America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 9. North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 10. North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 11. North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 12. North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 13. U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 14. U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 15. U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 16. U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 17. Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 18. Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 19. Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 20. Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 21. Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 22. Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 23. Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 24. Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 25. Europe acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 26. Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 27. Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 28. Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 29. Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 30. UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 31. UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 32. UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 33. UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 34. Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 35. Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 36. Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 37. Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 38. France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 39. France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 40. France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 41. France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 42. Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 43. Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 44. Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 45. Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 46. Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 47. Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 48. Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 49. Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 50. Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 51. Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 52. Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 53. Denmark acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 54. Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 55. Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 56. Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 57. Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 58. Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 59. Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 60. Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 61. Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 62. Asia Pacific acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 63. Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 64. Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 65. Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 66. Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 67. China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 68. China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 69. China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 70. China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 71. Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 72. Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 73. Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 74. Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 75. India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 76. India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 77. India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 78. India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 79. Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 80. Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 81. Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 82. Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 83. South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 84. South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 85. South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 86. South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 87. Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 88. Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 89. Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 90. Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 91. Latin America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 92. Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 93. Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 94. Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 95. Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 96. Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 97. Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 98. Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 99. Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 100. Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 101. Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 102. Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 103. Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 104. Middle East & Africa Acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
Table 105. Middle East & Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 106. Middle East & Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 107. Middle East & Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 108. Middle East & Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 109. South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 110. South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 111. South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 112. South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 113. Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 114. Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 115. Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 116. Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 117. UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 118. UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 119. UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 120. UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 121. Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 122. Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 123. Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 124. Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Acute myeloid leukemia treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and route of administration outlook (USD Million)
Fig. 10 End use outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Acute myeloid leukemia treatment market dynamics
Fig. 13 Acute myeloid leukemia treatment market: Porter’s five forces analysis
Fig. 14 Acute myeloid leukemia treatment market: PESTLE analysis
Fig. 15 Acute myeloid leukemia treatment market: Disease segment dashboard
Fig. 16 Acute myeloid leukemia treatment market: Disease market share analysis, 2024 & 2030
Fig. 17 Myeloblastic leukemia market, 2018 - 2030 (USD Million)
Fig. 18 Myelomonocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 19 Promyelocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 20 Monocytic leukemia market, 2018 - 2030 (USD Million)
Fig. 21 Other diseases market, 2018 - 2030 (USD Million)
Fig. 22 Acute myeloid leukemia treatment market: Treatment segment dashboard
Fig. 23 Acute myeloid leukemia treatment market: Treatment market share analysis, 2024 & 2030
Fig. 24 Chemotherapy market, 2018 - 2030 (USD Million)
Fig. 25 Anti-metabolites market, 2018 - 2030 (USD Million)
Fig. 26 Alkylating agents market, 2018 - 2030 (USD Million)
Fig. 27 Anthracycline drugs market, 2018 - 2030 (USD Million)
Fig. 28 Others market, 2018 - 2030 (USD Million)
Fig. 29 Targeted therapy market, 2018 - 2030 (USD Million)
Fig. 30 FLT3 inhibitors market, 2018 - 2030 (USD Million)
Fig. 31 Rydapt market, 2018 - 2030 (USD Million)
Fig. 32 Vanflyta market, 2018 - 2030 (USD Million)
Fig. 33 Xospata market, 2018 - 2030 (USD Million)
Fig. 34 IDH inhibitors market, 2018 - 2030 (USD Million)
Fig. 35 Tibsovo market, 2018 - 2030 (USD Million)
Fig. 36 Rezlidhia market, 2018 - 2030 (USD Million)
Fig. 37 Idhifa market, 2018 - 2030 (USD Million)
Fig. 38 Mylotarg market, 2018 - 2030 (USD Million)
Fig. 39 BCL-2 inhibitor market, 2018 - 2030 (USD Million)
Fig. 40 Hedgehog pathway inhibitor market, 2018 - 2030 (USD Million)
Fig. 41 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 42 Bispecific antibodies market, 2018 - 2030 (USD Million)
Fig. 43 Antibody-drug conjugates market, 2018 - 2030 (USD Million)
Fig. 44 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
Fig. 45 Chimeric Antigen Receptor (CAR) T-cell therapy market, 2018 - 2030 (USD Million)
Fig. 46 Other treatments market, 2018 - 2030 (USD Million)
Fig. 47 Acute myeloid leukemia treatment market: Route of administration segment dashboard
Fig. 48 Acute myeloid leukemia treatment market: Route of administration market share analysis, 2024 & 2030
Fig. 49 Parenteral market, 2018 - 2030 (USD Million)
Fig. 50 Oral market, 2018 - 2030 (USD Million)
Fig. 51 Acute myeloid leukemia treatment market: End use segment dashboard
Fig. 52 Acute myeloid leukemia treatment market: End use market share analysis, 2024 & 2030
Fig. 53 Hospitals and clinics market, 2018 - 2030 (USD Million)
Fig. 54 Specialty centers market, 2018 - 2030 (USD Million)
Fig. 55 Homecare setting market, 2018 - 2030 (USD Million)
Fig. 56 Ambulatory care centers market, 2018 - 2030 (USD Million)
Fig. 57 Acute myeloid leukemia treatment market revenue, by region
Fig. 58 Regional marketplace: Key takeaways
Fig. 59 Regional marketplace: Key takeaways
Fig. 60 North America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 61 U.S. country dynamics
Fig. 62 U.S. acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 63 Canada country dynamics
Fig. 64 Canada acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 65 Mexico country dynamics
Fig. 66 Mexico acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 67 Europe acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 68 UK country dynamics
Fig. 69 UK acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 70 Germany country dynamics
Fig. 71 Germany acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 72 France country dynamics
Fig. 73 France acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 74 Italy country dynamics
Fig. 75 Italy acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 76 Spain country dynamics
Fig. 77 Spain acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 78 Norway country dynamics
Fig. 79 Norway acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 80 Sweden country dynamics
Fig. 81 Sweden acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 82 Denmark country dynamics
Fig. 83 Denmark acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 84 Asia Pacific acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 85 Japan country dynamics
Fig. 86 Japan acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 87 China country dynamics
Fig. 88 China acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 89 India country dynamics
Fig. 90 India acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 91 Australia country dynamics
Fig. 92 Australia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 93 South Korea country dynamics
Fig. 94 South Korea acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 95 Thailand country dynamics
Fig. 96 Thailand acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 97 Latin America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 98 Brazil country dynamics
Fig. 99 Brazil acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 100 Argentina country dynamics
Fig. 101 Argentina acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 102 MEA acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 103 South Africa country dynamics
Fig. 104 South Africa acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 105 Saudi Arabia country dynamics
Fig. 106 Saudi Arabia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 107 UAE country dynamics
Fig. 108 UAE acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 109 Kuwait country dynamics
Fig. 110 Kuwait acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
Fig. 111 Company categorization
Fig. 112 Company market position analysis
Fig. 113 Strategic framework
Companies Mentioned
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- DAIICHI SANKYO COMPANY, LIMITED
- Jazz Pharmaceuticals plc
- Novartis AG
- Otsuka Pharmaceuticals Co.,Ltd.
- Pfizer Inc.
- Rigel Pharmaceuticals, Inc.
- Merck KGaA
- Sanofi
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | March 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.47 Billion |
| Forecasted Market Value ( USD | $ 6.29 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
